Development of Pharmacological Therapies in Acute Decompensated Heart Failure
Article Sidebar
Main Article Content
Abstract
ABSTRACT
Background: Acute decompensated heart failure is a cardiac disease that manifested from a chronic heart failure or occurred as de novo. With its high prevalence, there are many developments and innovations regarding its pharmacological therapies.
Methods: This article was written using the literature review method, involving 24 sources from english journals and a book as a result of literature searching from Google Scholar search engine.
Discussion: Disturbance of neurohormonal control results in acute decompensated heart failure indicated by an abnormally increased fluid in blood plasma that manifest in many abnormalities regarding the heart and lungs. Sympathetic nervous systems, renin-angiotensin-aldosterone system, arginine vasopressin, and natriuretic peptide have increased in functions and concentrations that played roles in failure of neurohormonal control of heart. Besides, heart failure causes release of several molecules like adrenomedullin and cardiac troponin. Several pharmacological therapies developed as managements of acute decompensated heart failure, such as adrecizumab, sacubitril-valsartan, nitroxyl donor, and diuretics.
Conclusion: Researches regarding pharmacological therapies to acute decompensated heart failure need to be continued to be done in finding new therapies and developing previously used therapies.
Keywords: acute decompensated heart failure, therapy
Article Details
References
2. Amsterdam E, Venugopal S, Thinda A. Pathophysiology of Acute Decompensated Heart Failure. Contemporary Cardiology. 2017;:81-88.
3. Onwuanyi A, Taylor M. Acute Decompensated Heart Failure: Pathophysiology and Treatment. The American Journal of Cardiology. 2007;99(6):S25-S30.
4. Velazquez E, Morrow D, DeVore A, Duffy C, Ambrosy A, McCague K et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine. 2019;380(6):539-548.
5. Joseph S, Cedars A, Ewald G, Geltman E, Mann D. Acute Decompensated Heart Failure. Texas Heart. 2009;36(6):510-520.
6. Fishbein D. Acute Decompensated Heart Failure: Classification, Epidemiology and Pathophysiology. Heart Failure. 2017;:149-170.
7. Hammond D, Smith M, Lee K, Honein D, Quidley A. Acute Decompensated Heart Failure. Journal of Intensive Care Medicine. 2016;33(8):456-466.
8. Voors A, Kremer D, Geven C, ter Maaten J, Struck J, Bergmann A et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. European Journal of Heart Failure. 2018;21(2):163-171.
9. Tsuruda T, Kato J, Kuwasako K, Kitamura K. Adrenomedullin: Continuing to explore cardioprotection. Peptides. 2019;111:47-54.
10. Pandhi P, Maaten J, Emmens J, Struck J, Bergmann A, Cleland J et al. Clinical value of pre‐discharge bio‐adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. European Journal of Heart Failure. 2019;22(4):683-691.
11. Geven C, Kox M, Pickkers P. Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. Frontiers in Immunology. 2018;9.
12. Carballo D, Stirnemann J, Garin N, Marti C, Serratrice J, Carballo S. Eligibility for sacubitril–valsartan in patients with acute decompensated heart failure. ESC Heart Failure. 2020;7(3):1282-1290.
13. Chang H, Chen K, Fong M, Feng A, Fu H, Huang K et al. Recovery of left ventricular dysfunction after sacubitril/valsartan: predictors and management. Journal of Cardiology. 2020;75(3):233-241.
14. Morrow D, Velazquez E, DeVore A, Desai A, Duffy C, Ambrosy A et al. Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial. Circulation. 2019;139(19):2285-2288.
15. Morrow D, Velazquez E, DeVore A, Prescott M, Duffy C, Gurmu Y et al. Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial. European Heart Journal. 2019;40(40):3345-3352.
16. McMurray J, Krum H, Abraham W, Dickstein K, Køber L, Desai A et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. New England Journal of Medicine. 2016;374(16):1521-1532.
17. Brisco‐Bacik M, ter Maaten J, Houser S, Vedage N, Rao V, Ahmad T et al. Outcomes Associated With a Strategy of Adjuvant Metolazone or High‐Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis. Journal of the American Heart Association. 2018;7(18).
18. Steuber T, Janzen K, Howard M. A Systematic Review and Meta‐Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2020;.
19. Bohn B, Hadgu R, Pope H, Shuster J. Oral Metolazone Versus Intravenous Chlorothiazide as an Adjunct to Loop Diuretics for Diuresis in Acute Decompensated Heart Failure With Reduced Ejection Fraction. Hospital Pharmacy. 2018;54(6):351-357.
20. Shulenberger C, Jiang A, Devabhakthuni S, Ivaturi V, Liu T, Reed B. Efficacy and Safety of Intravenous Chlorothiazide versus Oral Metolazone in Patients with Acute Decompensated Heart Failure and Loop Diuretic Resistance. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2016;36(8):852-860. 21. Parissis J, Bistola V, Ikonomidis I, Triposkiadis F. Nitroxyl donors for acute heart failure: promising newcomers. European Journal of Heart Failure. 2017;19(10):1333-1334.
22. Kemp-Harper B, Horowitz J, Ritchie R. Therapeutic Potential of Nitroxyl (HNO) Donors in the Management of Acute Decompensated Heart Failure. Drugs. 2016;76(14):1337-1348.
23. Felker G, Borentain M, Cleland J, DeSouza M, Kessler P, O'Connor C et al. Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure. European Journal of Heart Failure. 2019;21(8):1022-1031.
24. Sun H, Wu Z, Cao L, Zhu M, Nie X, Huang D et al. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology. Pharmacological Research. 2020;159:104961.